BioSpace News Archive

Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI), Rensselaer, New York, today announced transplantation of the cell product RPESC-RPE-4W into the first participant with dry age-related macular degeneration (dry AMD) in its Phase 1/2a clinical trial (NCT04627428) being conducted at the University of Michigan Kellogg Eye Center.

Noveome Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to the company’s lead product ST266 for the treatment of Necrotizing Enterocolitis (NEC).

PrecisionOS ® is now offering immersive virtual reality (VR) training in partnership with Siemens Healthineers.

Embleema Inc. and CDISC have announced a collaboration to develop new standards for experimental assays and bioinformatics protocols to facilitate monitoring the activity of Cell and Gene Therapy Products (CGTP).

FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm.

Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS.

Acutis, a specialized clinical and biosciences company, announced Dr. Abdel Halim has joined as Chief Scientific Officer and Executive Vice President.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced the presentation of an investigator-initiated in vitro study evaluating the efficacy of crofelemer, the company’s plant-based prescription drug.

Global health services company Cigna Corporation (NYSE: CI) announced today that Brian Evanko, executive vice president and chief financial officer, will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 in Rancho Palos Verdes, CA.

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, announced today that it has received FDA 510(k) clearance for its Rapid PE Triage & Notification product for fast identification and communication of suspected central pulmonary embolism — further strengthening RapidAI’s industry-leading clinical AI platform.